Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab for lean body mass and physical performance after hip fracture surgery
jRCT2080222609Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of bimagrumab in hip fracture (3 arms), sponsored by Novartis. Primary endpoints: Total lean body mass change and Physical performance. Started Sep 2014; status: completed.
02
Drugs
bimagrumab
03
Conditions
hip fracture
Beyond the preview
Go deeper on jRCT2080222609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222609.